Spectrum yanks marketing application for Neulasta rival after FDA demands more data
Months after Spectrum Pharmaceuticals informed investors that the FDA had denied its lung cancer drug poziotinib the breakthrough therapy status tag, the drugmaker said it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
